Your browser doesn't support javascript.
loading
Visceral disease in castration-resistant prostate cancer.
Pezaro, C; Omlin, A; Lorente, D; Rodrigues, D Nava; Ferraldeschi, R; Bianchini, D; Mukherji, D; Riisnaes, R; Altavilla, A; Crespo, M; Tunariu, N; de Bono, J; Attard, G.
Afiliación
  • Pezaro C; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Omlin A; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Lorente D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Rodrigues DN; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Ferraldeschi R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Bianchini D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Mukherji D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Riisnaes R; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Altavilla A; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Crespo M; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Tunariu N; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • de Bono J; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
  • Attard G; Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.
Eur Urol ; 65(2): 270-273, 2014 Feb.
Article en En | MEDLINE | ID: mdl-24295792
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Neoplasias de la Próstata Resistentes a la Castración / Neoplasias Hepáticas / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Eur Urol Año: 2014 Tipo del documento: Article País de afiliación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Neoplasias de la Próstata Resistentes a la Castración / Neoplasias Hepáticas / Neoplasias Pulmonares Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Eur Urol Año: 2014 Tipo del documento: Article País de afiliación: Reino Unido